Beksaç, MeralGarcia, Esther GonzalezDelimpasi, SosanaRobak, PawelKarunanithi, Kamaraj2025-06-032025-06-032024Beksac, M., Garcia, E. G., Delimpasi, S., Robak, P., Karunanithi, K., De Arriba, F., ... & Dimopoulos, M. A. (2024). Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide. Blood, 144, 4731.0006-497110.1182/blood-2024-199282https://hdl.handle.net/20.500.12713/7273Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomideeninfo:eu-repo/semantics/closedAccessHematologyBelantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including LenalidomideArticle14447314733WOS:001416739600035Q110.1182/blood-2024-199282